Navigation Links
The Leukemia & Lymphoma Society Targets Research in Four Critical Areas of Unmet Medical Need
Date:12/14/2010

WHITE PLAINS, N.Y., Dec. 14, 2010 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is taking an aggressive approach to tackling the challenge of improving outcomes for patients with cancers that remain stubbornly resistant to treatment.  As it has for more than 62 years, LLS will continue to accept applications from the world's best and brightest scientists to advance progress in all areas of blood cancer, and award grants based on merit.  In addition LLS has identified four specific areas of need, and is soliciting applications from scientists and physicians who are working on these difficult problems.

"We are charting the course by identifying and prioritizing the areas of need and directing funding to research that shows the most promise for improving survival and quality of life for patients with these particular diseases," said Louis DeGennaro, Ph.D., LLS chief mission officer.  "LLS wants to deliver better treatments, faster, to patients, and we have developed an innovative, strategic approach to achieve this goal."

LLS is issuing requests for proposals (RFP) from researchers working in the following areas:

  • Identification and characterization of the leukemic stem cell in acute myeloid leukemia and myelodysplastic syndrome and the identification of potential targeted therapies
  • Novel therapeutic strategies for non-cutaneous T-cell lymphoproliferative disorders
  • Development of therapeutic strategies for the high risk myeloma patient
  • Mechanisms underlying long term and late effects resulting from cancer treatment and the development measures to significantly reduce or prevent these toxicities

  • Applications responsive to these RFPs should be submitted under LLS's Translational Research Program, a program designed to help accelerate the movement of promising discoveries from the lab to the clinic.  A detailed description of the LLS Translational Research Program and application instructions are available here.

    About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

    Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.Contact: Andrea Greif(914) 821-8958andrea.greif@lls.org
    '/>"/>

    SOURCE The Leukemia & Lymphoma Society
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
    2. Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
    3. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
    4. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
    5. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
    6. Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
    7. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
    8. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
    9. Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
    10. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
    11. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
    (Date:3/24/2017)... , Mar 24, 2017 The Board ... the company,s Annual Report 2016 including the complete 2016 Annual ... and available on Nordic Nanovector,s website in the section Investor ... ... IR enquiries: Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ...
    (Date:3/23/2017)... PUNE, India , March 23, 2017 ... are growing ageing population, increasing diabetic population, accelerating economic growth ... developments of this industry are higher life expectancy of ESRD ... potential in emerging markets. However, the expansion of the market ... ...
    Breaking Medicine Technology:
    (Date:3/24/2017)... ... March 24, 2017 , ... ... of enhancements, upgrading their training and leads programs. , In February, 2017, Empower ... elite sales agents, Performance Partners is designed to teach how to maximize their ...
    (Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming ... the creation of published author, Wesley Gerboth, a World War II veteran, with a ... Now, at age ninety-one, he shares the Wisdom God bestowed upon him in this ...
    (Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, ... and silly dog who lives his life to the fullest, as God intended. “The ... author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially about ...
    (Date:3/23/2017)... ... , ... The physicians of KSF Orthopaedic Center PA are proud to announce ... is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside ... patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with ...
    (Date:3/23/2017)... ... March 23, 2017 , ... ... Convention Center at 10 North Broadway Avenue, will be an educational and exciting ... practical instruction in the management of chronic pain. , Oklahoma is in a ...
    Breaking Medicine News(10 mins):